Selumetinib is currently FDA approved for children 2 years and older with symptomatic and inoperable plexiform neurofibromas.

If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for ...

Panelists discuss how MEK inhibitors, such as trametinib and selumetinib, are emerging as first-line treatments for symptomatic NF1-associated plexiform neurofibromas, especially in progressive or ...

Panelists discuss how mutations in the NF1 gene lead to loss of neurofibromin function, resulting in hyperactivation of the RAS/MAPK and PI3K/AKT/mTOR pathways, and how this molecular ...

EMA committee recommends marketing approval for SpringWorks’ mirdametinib to treat adult & paediatric patients with NF1-PN: Stamford, Connecticut Tuesday, May 27, 2025, 12:00 Hr ...

The Philippine Food and Drug Administration approves a game-changing prescription medicine, Selumetinib.

ABSTRACT: The aim of this work is to review the management of compressive cervical neurofibrosarcoma. We report the case of a 45-year-old female housewife patient (DT) with no medical or surgical ...

Pasithea Therapeutics has announced the start of a Phase I/Ib open-label trial of macrocyclic mitogen-activated protein kinase (MEK) inhibitor, PAS-004, for treating adults with neurofibromatosis type ...

As of the cut-off date of April 2, 2025, a total of 21 patients had been enrolled and received at least one dose of PAS-004 ...

SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

“Surgical removal of plexiform neurofibromas can be challenging and is often not possible, so if approved, mirdametinib could be an important treatment option for children and adult patients in Europe ...